Beta-lactamases with improved properties for therapy
AssigneeSynthetic Biologics, Inc.
InventorsMichael Kaleko, Sheila Connelly
Life of this patent
Estimating the term…
Abstract
This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
Claims32
1-73. (canceled)
A beta-lactamase comprising an amino acid sequence having at least 95% sequence identity with SEQ ID NO:
- 1 and having a polar and neutral hydrophilic residue other than alanine (A) at position 238 according to Ambler classification.
A method for preventing an antibiotic-induced adverse effect in the gastrointestinal (GI) tract, comprising administering an effective amount of a beta-lactamase to a patient in need thereof, wherein the beta-lactamase comprises an amino acid sequence having at least 95% sequence identity with SEQ ID NO:
- 1 and having a polar and neutral hydrophilic residue other than alanine (A) at position 238 according to Ambler classification.
Dependencies are inferred from the claim text.